Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys.

[1]  Charles N Serhan,et al.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. , 2018, Journal of Clinical Investigation.

[2]  P. Treuting,et al.  Obstructive Lymphangitis Precedes Colitis in Murine Norovirus-Infected Stat1-Deficient Mice. , 2018, The American journal of pathology.

[3]  D. Gilroy,et al.  Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli–driven acute inflammation , 2018, JCI insight.

[4]  J. Sivak,et al.  Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury , 2017, The Journal of clinical investigation.

[5]  L. Peyrin-Biroulet,et al.  MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. , 2017, Gastroenterology.

[6]  S. Danese,et al.  Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases , 2017, Front. Immunol..

[7]  B. Jacquelin,et al.  Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys , 2017, Nature Medicine.

[8]  A. Sher,et al.  Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy , 2017, Science Translational Medicine.

[9]  T. Petrova,et al.  Intestinal lymphatic vasculature: structure, mechanisms and functions , 2017, Nature Reviews Gastroenterology &Hepatology.

[10]  M. Perretti,et al.  Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection , 2017, Proceedings of the National Academy of Sciences.

[11]  K. Caron,et al.  Lymphatic deletion of calcitonin receptor-like receptor exacerbates intestinal inflammation. , 2017, JCI insight.

[12]  C. Serhan,et al.  Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics. , 2017, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  B. Zinselmeyer,et al.  Lymphoid Aggregates Remodel Lymphatic Collecting Vessels that Serve Mesenteric Lymph Nodes in Crohn Disease. , 2016, The American journal of pathology.

[14]  M. Perretti,et al.  Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation , 2016, The Journal of Immunology.

[15]  K. Tomita,et al.  Platelet interaction with lymphatics aggravates intestinal inflammation by suppressing lymphangiogenesis. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[16]  Derek W. Gilroy,et al.  Resolution of inflammation: a new therapeutic frontier , 2016, Nature Reviews Drug Discovery.

[17]  Aaron R Navratil,et al.  A Critical Role for Monocytes/Macrophages During Intestinal Inflammation-associated Lymphangiogenesis , 2016, Inflammatory bowel diseases.

[18]  D. Granger,et al.  Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease , 2016, Circulation.

[19]  Mauro M. Teixeira,et al.  Resolution of Inflammation: What Controls Its Onset? , 2016, Front. Immunol..

[20]  H. V. Van Kruiningen.  An Infectious Pig Model of Crohn's Disease. , 2016, Inflammatory bowel diseases.

[21]  C. Serhan,et al.  Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes , 2015, Infection and Immunity.

[22]  C. Piantadosi,et al.  The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. , 2015, American journal of respiratory cell and molecular biology.

[23]  P. Choyke,et al.  Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection , 2015, Nature Communications.

[24]  D. Zawieja,et al.  IL‐1β reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase‐2 and prostaglandin E2 , 2015, British Journal of Pharmacology.

[25]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[26]  F. Abreo,et al.  Downregulation of FoxC2 Increased Susceptibility to Experimental Colitis: Influence of Lymphatic Drainage Function? , 2015, Inflammatory bowel diseases.

[27]  C. Serhan,et al.  Proresolving Nanomedicines Activate Bone Regeneration in Periodontitis , 2015, Journal of dental research.

[28]  C. Thiemermann,et al.  Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis , 2014, Proceedings of the National Academy of Sciences.

[29]  A. Gandelli,et al.  VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. , 2014, The Journal of clinical investigation.

[30]  Soonkyu Chung,et al.  Dietary Cholesterol Promotes Adipocyte Hypertrophy and Adipose Tissue Inflammation in Visceral, but Not in Subcutaneous, Fat in Monkeys , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[31]  J. Alexander,et al.  Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms. , 2014, Lymphology.

[32]  C. Comin,et al.  Preliminary Results of the Influence of the In Vivo Use of a Lymphatic Dye (Patent Blue V) in the Surgical Treatment of Crohn’s Disease , 2014, Surgical innovation.

[33]  C. Serhan,et al.  Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.

[34]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[35]  P. J. Armstrong,et al.  Clinical Features, Intestinal Histopathology, and Outcome in Protein‐Losing Enteropathy in Yorkshire Terrier Dogs , 2014, Journal of veterinary internal medicine.

[36]  M. Lu,et al.  Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. , 2014, The Journal of clinical investigation.

[37]  P. Calder,et al.  Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. , 2014, Journal of Crohn's & colitis.

[38]  P. Calder,et al.  Altered Colonic Mucosal Polyunsaturated Fatty Acid (PUFA) Derived Lipid Mediators in Ulcerative Colitis: New Insight into Relationship with Disease Activity and Pathophysiology , 2013, PloS one.

[39]  O. Yoo,et al.  Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes. , 2013, Blood.

[40]  J. Calixto,et al.  Maresin 1, a Proresolving Lipid Mediator Derived from Omega-3 Polyunsaturated Fatty Acids, Exerts Protective Actions in Murine Models of Colitis , 2013, The Journal of Immunology.

[41]  J. Sundberg,et al.  Blockade of VEGF Receptor-3 Aggravates Inflammatory Bowel Disease and Lymphatic Vessel Enlargement , 2013, Inflammatory bowel diseases.

[42]  M. Perretti,et al.  A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. , 2013, Blood.

[43]  G. Koh,et al.  Regulation and implications of inflammatory lymphangiogenesis. , 2012, Trends in immunology.

[44]  J. Wallace,et al.  Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis , 2012, PloS one.

[45]  Y. Yatomi,et al.  Platelet Activation Receptor CLEC-2 Regulates Blood/Lymphatic Vessel Separation by Inhibiting Proliferation, Migration, and Tube Formation of Lymphatic Endothelial Cells* , 2012, The Journal of Biological Chemistry.

[46]  Charles N. Serhan,et al.  Infection Regulates Pro-Resolving Mediators that Lower Antibiotic Requirements , 2012, Nature.

[47]  K. Alitalo,et al.  The lymphatic vasculature in disease , 2011, Nature Medicine.

[48]  L. Dubuquoy,et al.  Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[49]  J. Calixto,et al.  Omega-3 Fatty Acid-Derived Mediators 17(R)-Hydroxy Docosahexaenoic Acid, Aspirin-Triggered Resolvin D1 and Resolvin D2 Prevent Experimental Colitis in Mice , 2011, The Journal of Immunology.

[50]  Philippe Seksik,et al.  Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.

[51]  A. Griffiths,et al.  Maintenance of remission in inflammatory bowel disease using omega‐3 fatty acids (fish oil): A systematic review and meta‐analyses , 2011, Inflammatory bowel diseases.

[52]  Pilhan Kim,et al.  Podoplanin-Expressing Cells Derived From Bone Marrow Play a Crucial Role in Postnatal Lymphatic Neovascularization , 2010, Circulation.

[53]  M. Lu,et al.  Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. , 2010, Blood.

[54]  T. Azuma,et al.  Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium–induced colitis , 2008, Inflammatory bowel diseases.

[55]  C. Serhan,et al.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.

[56]  A. Griffiths,et al.  Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[57]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[58]  C. Serhan,et al.  Anti-inflammatory and proresolving lipid mediators. , 2008, Annual review of pathology.

[59]  C. Serhan,et al.  Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  J. Colombel,et al.  The forgotten role of lymphangitis in Crohn’s disease , 2007, Gut.

[61]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[62]  C. Ligorio,et al.  Lymphangiogenesis in Crohn’s disease: an immunohistochemical study using monoclonal antibody D2-40 , 2007, Virchows Archiv.

[63]  W. MacNaughton,et al.  Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[64]  M. Mangino,et al.  Lipoxin biosynthesis in inflammatory bowel disease. , 2006, Prostaglandins & other lipid mediators.

[65]  D. Kerjaschki,et al.  Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants , 2006, Nature Medicine.

[66]  K. Maruyama,et al.  Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. , 2005, The Journal of clinical investigation.

[67]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  C. Serhan,et al.  Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins1 , 2005, The Journal of Immunology.

[69]  J. Parkinson,et al.  A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Perretti,et al.  Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. , 2003, Blood.

[71]  S. Schoppmann,et al.  Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease , 2003, Virchows Archiv.

[72]  G. Kollias,et al.  Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor–induced Crohn's-like Inflammatory Bowel Disease , 2002, The Journal of experimental medicine.

[73]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[74]  A. Young,et al.  Lipoxin A4 Analogs Attenuate Induction of Intestinal Epithelial Proinflammatory Gene Expression and Reduce the Severity of Dextran Sodium Sulfate-Induced Colitis1 , 2002, The Journal of Immunology.

[75]  J. Berg,et al.  Divergent effects of tumor necrosis factor α on apoptosis of human neutrophils , 2001, Journal of Leukocyte Biology.

[76]  T. Kuijpers,et al.  Divergent effects of tumor necrosis factor alpha on apoptosis of human neutrophils. , 2000, Journal of leukocyte biology.

[77]  C. Clish,et al.  Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  G. Kollias,et al.  Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice , 1997, European journal of immunology.

[79]  C. Serhan,et al.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. , 1993, The Journal of clinical investigation.

[80]  C. Serhan,et al.  Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. , 1990, The Journal of clinical investigation.

[81]  D. W. Hayden,et al.  Lipogranulomatous Lymphangitis in Canine Intestinal Lymphangiectasia , 1984, Veterinary pathology.

[82]  L. E. Hughes,et al.  Mesenteric lymphatic obstruction in Crohn's disease. , 1980, Digestion.

[83]  H. Saloniemi,et al.  Experimental regional enteritis in pigs. , 1976, Scandinavian journal of gastroenterology.

[84]  J. Bruna.  Types of collateral lymphatic circulation. , 1974, Lymphology.

[85]  Kalima Tv.  Experimental lymphatic obstruction in the ileum. , 1970 .

[86]  Y. Collan,et al.  Intestinal villus in experimental lymphatic obstruction. Correlation of light and electron microscopic findings with clinical diseases. , 1970, Scandinavian journal of gastroenterology.

[87]  T. Kalima.  Experimental lymphatic obstruction in the ileum. , 1970, Annales chirurgiae et gynaecologiae Fenniae.

[88]  J. Burn.  Obstructive lymphopathy. , 1968, Annals of the Royal College of Surgeons of England.